3 recruiting, 1 not yet recruiting. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Not yet recruiting 1 |
| Phase 2 | 2 | Recruiting 2 |
Follow Ris-Rez: new trials by email Literature Review of Ris-Rez trials Research Report on Ris-Rez
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC HS-20093 for Injection, ZG006, Adebrelimab Injection - Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 1 | Not yet recruiting | Hansoh BioMedical R&D Company | 338 | 2026-11-15 | 2026-10-23 |
| A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations HS-20093 for Injection, Adebrelimab Injection - Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Hansoh BioMedical R&D Company | 76 | 2026-10-08 | 2026-10-23 |
| A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202) Ris-Rez, G-CSF - Sarcoma | Phase 1 / Phase 2 | Recruiting | GlaxoSmithKline | 64 | 2026-06-22 | 2026-10-01 |
| A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) Ris-Rez, Cisplatin, Carboplatin - Neoplasms | Phase 1 | Recruiting | GlaxoSmithKline | 845 | 2024-09-30 | 2026-05-22 |
Carcinoma, Non-Small-Cell Lung (1) · Neoplasms (1) · Sarcoma (1) · Small Cell Lung Carcinoma (1)
GlaxoSmithKline (2) · Hansoh BioMedical R&D Company (2)
Canada (2) · France (2) · Israel (2) · Japan (2) · United Kingdom (2) · United States (2) · Argentina (1) · China (1) · Hong Kong (1) · Italy (1) · Panama (1) · South Korea (1) · Spain (1) · Taiwan (1)
2025 (1)